Table 5.
The role of Belatacept in VCA clinical practice.
| References | Gender, Age | VCA | Timing | Rejection |
|---|---|---|---|---|
| Cendales et al. (25) | Female, 21 | Unilateral hand | 12 months (conversion) | No |
| Krezdorn et al. (101) | Male, NR | Face | 14 months (conversion) | Yes (BRR) |
| Grahammer et al. (39) | Males (4 pts), NR | 2 Bilateral Hand, 1 Bilateral hand & forearm, 1 Unilateral hand | 3 months−13 years (conversion) | Yes (2 pts) |
| Cendales et al. (37) | Male, 54 | Unilateral hand | Initial maintenance | Yes |
Pts, patients; BRR, Belatacept resistant rejection.